Research map: Clinical impact of 18F-FES PET/CT-detected ER-positive conversion in metastatic breast cancer with ER-negative primary tumors

Back to the article

Papers in this map

  1. Breast cancer statistics 2024 · Angela N. Giaquinto · 2024 · 767 citations · Cited by this paper
  2. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort · 2026 · Related
  3. Progesterone receptor modulates ERα action in breast cancer · Hisham Mohammed · 2015 · 681 citations · Cited by this paper
  4. Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma · 2026 · Related
  5. Current issues in ER and HER2 testing by IHC in breast cancer · Allen M. Gown · 2008 · 384 citations · Cited by this paper
  6. Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer · 2026 · Related
  7. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies · Nicolas Aide · 2017 · 362 citations · Cited by this paper
  8. From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment · 2026 · Related
  9. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis · Willemijne A.M.E. Schrijver · 2017 · 317 citations · Cited by this paper
  10. [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice · 2026 · Related
  11. The Role of Progesterone Receptors in Breast Cancer · Zhuo Li · 2022 · 263 citations · Cited by this paper
  12. CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease · 2026 · Related
  13. PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma · Michel van Kruchten · 2012 · 166 citations · Cited by this paper
  14. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy · 2026 · Related
  15. Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer · Yunhai Li · 2020 · 154 citations · Cited by this paper
  16. In vivo multimodal PET/MRI imaging and plasma biomarkers implicate glymphatic dysfunction linking neuroinflammation to tau pathology in the early Alzheimer’s disease continuum · 2026 · Related
  17. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer · Brenda F. Kurland · 2016 · 128 citations · Cited by this paper
  18. Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer · 2026 · Related
  19. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study · Sun Young Chae · 2019 · 119 citations · Cited by this paper
  20. 68Ga-PSMA PET/CT in biochemically recurrent prostate cancer: association with genomic data · 2026 · Related
  21. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification · Emma H. Allott · 2016 · 117 citations · Cited by this paper
  22. A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC) · Lanell M. Peterson · 2013 · 108 citations · Cited by this paper
  23. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases · Laurien D.C. Hoefnagel · 2012 · 95 citations · Cited by this paper
  24. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort · Thomas Grinda · 2021 · 92 citations · Cited by this paper
  25. 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients · Hilde H. Nienhuis · 2018 · 61 citations · Cited by this paper
  26. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT · Zhongyi Yang · 2017 · 55 citations · Cited by this paper
  27. Value of18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study · Jorianne Boers · 2021 · 41 citations · Cited by this paper
  28. Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment · Cheng Liu · 2022 · 40 citations · Cited by this paper
  29. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[18F]Fluoro-17β-Estradiol PET · David A. Mankoff · 2023 · 39 citations · Cited by this paper
  30. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT · Gianluca Bottoni · 2021 · 32 citations · Cited by this paper
  31. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET · Alessandra Gennari · 2024 · 30 citations · Cited by this paper
  32. 18F-FES and 18F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment · Cheng Liu · 2023 · 20 citations · Cited by this paper
  33. Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological study · Zongbi Yi · 2020 · 19 citations · Cited by this paper
  34. 18F-Labeled Fluoroestradiol PET/CT: Current Status, Gaps in Knowledge, and Controversies—AJR Expert Panel Narrative Review · Matthew F. Covington · 2023 · 10 citations · Cited by this paper
  35. Impact of18F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer · Jeongryul Ryu · 2024 · 8 citations · Cited by this paper
  36. 18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Metaanalysis · Ashwin Singh Parihar · 2025 · 6 citations · Cited by this paper
  37. The Role of Estrogen Receptor–Targeted PET with 16α- 18 F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis · Jennifer M. Specht · 2025 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)